What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer Inc. stands out as an undervalued biotech stock with strong dividend potential and ambitious oncology expansion. The company boasts a forward P/E of 8.82, making it significantly cheaper than ...